Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 ADME and absolute bioavailability study of PF-04965842 in healthy men
NL-OMON45258Phase 1Active, not recruiting
- Sponsor
- Pfizer
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of abrocitinib in atopic dermatitis (AD) and systemic lupus erythematosus (SLE), sponsored by Pfizer. Primary endpoint: Rate and extent of radioactivity excretion. Started Jul 2017; status: active, not recruiting.
02
Drugs
abrocitinib
03
Conditions
atopic dermatitis (AD)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NL-OMON45258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45258.